Press Release

15 September 2025

HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor

Chengdu, China, September 15, 2025 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA), a clinical-stage biotechnology company based in Emeryville, CA, USA, on the initiation of a Phase 1 clinical study of BGE-102, a novel, potent NLRP3 inhibitor developed from a hit compound identified using HitGen's industry-leading DEL technology platform. The event triggers an undisclosed milestone payment to HitGen under the collaboration agreement between the two companies.
27 August 2025

DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

Start Your Journey to Access Vast Chemical Space
27 August 2025

Infographic | HitGen FY2025H1 Report

Infographic | HitGen FY2025H1 Report
04 July 2025

ESG | HitGen Releases Its Inaugural Sustainability Report

CHENGDU, China, July 4, 2025 – Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG") areas, as well as its sustainability practices and performance in the year of 2024, systematically addressing stakeholders' concerns.
04 June 2025

Delegation from UK Foreign, Commonwealth & Development Office Visited HitGen

On May 28, Catherine West, Parliamentary Under-Secretary of State (Indo-Pacific) at the Foreign, Commonwealth and Development Office of the UK, and Anthony Preston, British Consul General in Chongqing, along with their delegation, visited HitGen Inc. (SSE: 688222.SH). Dr. Jin Li, Chairman and CEO of HitGen, accompanied them throughout the visit.
25 April 2025

Infographic | HitGen FY2024&2025Q1 Report

Infographic | HitGen FY2024&2025Q1 Report
10 April 2025

Mission BioCapital Announces 2024 Platinum Ticket Investments and Opening of $4 Million 2025 Platinum Program Contest

Mission BioCapital (MBC), in partnership with sponsors Eli Lilly and Company (Lilly), Ono Venture Investment (OVI), Alloy Therapeutics, and our newest sponsor, HitGen, announced today that applications are open internationally for the 2025 Platinum Program. MBC's Platinum Program aims to advance high-potential life sciences start-up companies by providing pre-seed funding, global laboratory space, expert mentorship, and discovery services to accelerate their launch and initial development. Early-stage biotechnology innovators from around the globe are invited to apply.
26 December 2024

2025 Pre-Sale|Nucleic Acid Monomer Off 20%|100+ Special Monomers on the Shelf

2025 Pre-Sale Nucleic Acid Monomer Off 20% 100+ Special Monomers on the Shelf
25 October 2024

Infographic | HitGen FY2024 Q3 Report

Infographic | HitGen FY2024 Q3 Report
08 October 2024

Pharma Peers Unite to Build DNA-Encoded Libraries

Finding tools and hits for targets in drug discovery can feel like hunting for four leaf clovers in a blizzard. And researcher Sylvie Sakata was close to giving up on one discovery tool, DNA-encoded libraries, when a new consortium started to fall into place. Now this technology is garnering more interest for its potential to discover new molecular compounds, known as “hits,” to exponentially impact the early research efforts that can lead to potential new medicines.

News

Press Release

Thanks for reading!